shopping cart Your cart is empty
  • Home
  • Press Release
  • Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Is Expected To Reach US$ 1,162.1 Mn By 2025

Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Is Expected To Reach US$ 1,162.1 Mn By 2025

Oct 28, 2021

According to the latest market report published by Brisk insights “Polycystic Ovarian Syndrome (PCOS) Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025” the global polycystic ovarian syndrome (PCOS) therapeutics market was valued at US$ 784.74 Mn in 2016, and is expected to reach US$ 1,162.1 Mn by 2025, expanding at a CAGR of 4.47% from 2017 to 2025.  

Market Insights

Polycystic ovarian syndrome (PCOS) therapeutics market is expected to show significant market growth during the forecast period due to growing prevalence of PCOS, rising treatment awareness and significant unmet needs. For the purpose of study, global PCOS therapeutics market is segmented on the basis of drug type such as oral contraceptive, ovulation inducing agents, facial hair growth inhibitor, insulin sensitizing agent and others. In the base year 2016, oral contraceptive was major revenue contributing segment due to its effectiveness to regulate PCOS symptoms such as reduction of extra hair growth, lower risks for endometrial cancer, ovarian cancer, and ovarian cysts, cleansing the acne and to regulate the menstrual periods. PCOS therapeutics market is currently dominated by North America, factors such as higher cost of therapeutics, higher number of targeted population, government reimbursement policies in healthcare infrastructure and early diagnosis are fueling the growth of PCOS therapeutics market in North America. However, Asia-Pacific is  anticipated to show highest market growth during forecast period due to rising number of target population, improving healthcare infrastructure and increasing treatment awareness.

Browse the full report Polycystic Ovarian Syndrome (PCOS) Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2017 – 2025 at https://www.briskinsights.com/report/polycystic-ovarian-syndrome-pcos-therapeutics-market

Market Competition Assessment:

The polycystic ovarian syndrome (PCOS) therapeutics market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as Teva Pharmaceutical Industries Limited, Bristol Myers Squibb, Crinetics Pharmaceuticals, Inc., EffRx Inc., Ferring Pharmaceuticals, Merck KGaA, Neurocrine Biosciences, Inc., Novartis Pharmaceuticals, Pfizer Inc., Sanofi Aventis and other.

Key Market Movements:

  • Factors such as rising prevalence PCOS and increasing popularity of combination drugs are driving the market growth of PCOS therapeutics market worldwide.
  • Due to the high unmet needs, vendors in the market are focusing in development of ideal treatment, rising access for the treatment medication in some developing countries would fuel the growth of PCOS therapeutics market during forecast period.
  • Currently, there is large PCOS therapeutic market potential for new entrants due to lack of approved and efficient drug in market also absence of a strong pipeline molecules.
  • Lack of regulatory approved therapeutics and adverse effects associated with off-label products are negatively impacting the growth of PCOS therapeutics market globally.